Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies
Identifieur interne : 000638 ( PascalFrancis/Curation ); précédent : 000637; suivant : 000639Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies
Auteurs : Jens H. Kuhn [États-Unis, Allemagne] ; WENHUI LI [États-Unis] ; Sheli R. Radoshitzky [États-Unis] ; Hyeryun Choe [États-Unis] ; Michael Farzan [États-Unis]Source :
- Antiviral therapy : (London) [ 1359-6535 ] ; 2007.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
The identification in 2003 of a coronavirus as the aetiological agent of severe acute respiratory syndrome (SARS) intensified efforts to understand the biology of coronaviruses in general and SARS coronavirus (SARS-CoV) in particular. Rapid progress was made in describing the SARS-CoV genome, evolution and lifecycle. Identification of angiotensin-converting enzyme 2 (ACE2) as an obligate cellular receptor for SARS-CoV contributed to understanding of the SARS-CoV entry process, and helped to characterize two targets of antiviral therapeutics: the SARS-CoV spike protein and ACE2. Here we describe the role of these proteins in SARS-CoV replication and potential therapeutic strategies aimed at preventing entry of SARS-CoV into target cells.
pA |
|
---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000351
Links to Exploration step
Pascal:07-0427335Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies</title>
<author><name sortKey="Kuhn, Jens H" sort="Kuhn, Jens H" uniqKey="Kuhn J" first="Jens H." last="Kuhn">Jens H. Kuhn</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Wenhui Li" sort="Wenhui Li" uniqKey="Wenhui Li" last="Wenhui Li">WENHUI LI</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Radoshitzky, Sheli R" sort="Radoshitzky, Sheli R" uniqKey="Radoshitzky S" first="Sheli R." last="Radoshitzky">Sheli R. Radoshitzky</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Choe, Hyeryun" sort="Choe, Hyeryun" uniqKey="Choe H" first="Hyeryun" last="Choe">Hyeryun Choe</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pediatrics, Children's Hospital, Harvard Medical School</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Farzan, Michael" sort="Farzan, Michael" uniqKey="Farzan M" first="Michael" last="Farzan">Michael Farzan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0427335</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0427335 INIST</idno>
<idno type="RBID">Pascal:07-0427335</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000351</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000638</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies</title>
<author><name sortKey="Kuhn, Jens H" sort="Kuhn, Jens H" uniqKey="Kuhn J" first="Jens H." last="Kuhn">Jens H. Kuhn</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Wenhui Li" sort="Wenhui Li" uniqKey="Wenhui Li" last="Wenhui Li">WENHUI LI</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Radoshitzky, Sheli R" sort="Radoshitzky, Sheli R" uniqKey="Radoshitzky S" first="Sheli R." last="Radoshitzky">Sheli R. Radoshitzky</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Choe, Hyeryun" sort="Choe, Hyeryun" uniqKey="Choe H" first="Hyeryun" last="Choe">Hyeryun Choe</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Pediatrics, Children's Hospital, Harvard Medical School</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Farzan, Michael" sort="Farzan, Michael" uniqKey="Farzan M" first="Michael" last="Farzan">Michael Farzan</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral therapy : (London)</title>
<title level="j" type="abbreviated">Antivir. ther. : (Lond.)</title>
<idno type="ISSN">1359-6535</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral therapy : (London)</title>
<title level="j" type="abbreviated">Antivir. ther. : (Lond.)</title>
<idno type="ISSN">1359-6535</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Coronavirus</term>
<term>Severe acute respiratory syndrome</term>
<term>Targeted therapy</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
<term>Coronavirus</term>
<term>Traitement</term>
<term>Antiviral</term>
<term>Thérapeutique ciblée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The identification in 2003 of a coronavirus as the aetiological agent of severe acute respiratory syndrome (SARS) intensified efforts to understand the biology of coronaviruses in general and SARS coronavirus (SARS-CoV) in particular. Rapid progress was made in describing the SARS-CoV genome, evolution and lifecycle. Identification of angiotensin-converting enzyme 2 (ACE2) as an obligate cellular receptor for SARS-CoV contributed to understanding of the SARS-CoV entry process, and helped to characterize two targets of antiviral therapeutics: the SARS-CoV spike protein and ACE2. Here we describe the role of these proteins in SARS-CoV replication and potential therapeutic strategies aimed at preventing entry of SARS-CoV into target cells.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1359-6535</s0>
</fA01>
<fA03 i2="1"><s0>Antivir. ther. : (Lond.)</s0>
</fA03>
<fA05><s2>12</s2>
</fA05>
<fA06><s2>4</s2>
<s3>p. b</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Spotlight on respiratory viruses</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>KUHN (Jens H.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>WENHUI LI</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>RADOSHITZKY (Sheli R.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CHOE (Hyeryun)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>FARZAN (Michael)</s1>
</fA11>
<fA12 i1="01" i2="1"><s1>DE JONG (Menno D.)</s1>
<s9>ed.</s9>
</fA12>
<fA12 i1="02" i2="1"><s1>HAYDEN (Frederick G.)</s1>
<s9>ed.</s9>
</fA12>
<fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1>
<s2>Southborough, MA</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin</s1>
<s2>Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Pediatrics, Children's Hospital, Harvard Medical School</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA15 i1="01"><s1>Oxford University Clinical Research Unit, Hospital for Tropical Diseases</s1>
<s2>Ho Chi Minh City</s2>
<s3>VNM</s3>
<sZ>1 aut.</sZ>
</fA15>
<fA15 i1="02"><s1>University of Virginia School of Medicine</s1>
<s2>Charlotesville, VA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA15 i1="03"><s1>Global Influenza Program, World Health Organization</s1>
<s2>Geneva</s2>
<s3>CHE</s3>
<sZ>2 aut.</sZ>
</fA15>
<fA20><s1>639-650</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>27047</s2>
<s5>354000161541800060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>163 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0427335</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral therapy : (London)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The identification in 2003 of a coronavirus as the aetiological agent of severe acute respiratory syndrome (SARS) intensified efforts to understand the biology of coronaviruses in general and SARS coronavirus (SARS-CoV) in particular. Rapid progress was made in describing the SARS-CoV genome, evolution and lifecycle. Identification of angiotensin-converting enzyme 2 (ACE2) as an obligate cellular receptor for SARS-CoV contributed to understanding of the SARS-CoV entry process, and helped to characterize two targets of antiviral therapeutics: the SARS-CoV spike protein and ACE2. Here we describe the role of these proteins in SARS-CoV replication and potential therapeutic strategies aimed at preventing entry of SARS-CoV into target cells.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Thérapeutique ciblée</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Targeted therapy</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Terapéutica dirigida</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Poumon pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Lung disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Pulmón patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>281</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000638 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000638 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PascalFrancis |étape= Curation |type= RBID |clé= Pascal:07-0427335 |texte= Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |